Company news

GT Biopharma, Inc. news in 2025

GT Biopharma, Inc.'s news releases, calls and decks from 2025, newest first.

View company

GT Biopharma, Inc. (NASDAQ: GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

November 19, 2025

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 14, 2025

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

October 23, 2025

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory CD33 Expressing Hematologic Malignancies

October 9, 2025

GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit

October 6, 2025

GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 4, 2025

GT Biopharma Reports Second Quarter 2025 Financial Results

August 14, 2025

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

August 11, 2025

GT Biopharma Appoints New Member to its Board of Directors

June 13, 2025

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

May 19, 2025

GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit

March 4, 2025

GT Biopharma Announces Exercise of Warrants

February 25, 2025

GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement

February 25, 2025

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies

January 26, 2025

Decks in 2025